NanoViricides Reports NV-387 Outperforms Tamiflu and Xofluza Against H3N2 in Animal Studies

Reuters

01/13

NanoViricides Reports NV-387 Outperforms Tamiflu and Xofluza Against H3N2 in Animal Studies

NanoViricides Inc. has announced promising research results for its broad-spectrum antiviral drug candidate, NV-387. The company reports that NV-387 has demonstrated substantial superiority over existing treatments like Tamiflu and Xofluza in animal models of Influenza A/H3N2 lethal lung infection. NV-387 is also active against coronaviruses, RSV, and other viruses that use heparan sulfate features to infect human cells. The company emphasizes that NV-387’s unique mechanism makes it difficult for viruses to develop resistance, addressing a major limitation of current antiviral therapies. These findings highlight NV-387’s potential as a future dominant player in the treatment of acute and severe acute respiratory infections. The timeline for the presentation of these results has not been specified.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NanoViricides Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1126644) on January 13, 2026, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"澳洲华人首选美澳港股一站式交易平台 | 老虎证券","description":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","keywords":"老虎证券,老虎证券澳洲,老虎证券股票,老虎证券开户,老虎证券app,tigertrade老虎证券,股票,asx美股,炒股,券商,澳洲股票交易,澳大利亚炒股","social":{"ogDescription":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2603568254"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2603568254\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2603568254?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-13 21:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2603568254","market":"us","top_or_hot":-1,"title":"NanoViricides Reports NV-387 Outperforms Tamiflu and Xofluza Against H3N2 in Animal Studies","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      NanoViricides Reports NV-387 Outperforms Tamiflu and Xofluza Against H3N2 in Animal Studies\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/NNVC\">NanoViricides Inc.</a> has announced promising research results for its broad-spectrum antiviral drug candidate, NV-387. The company reports that NV-387 has demonstrated substantial superiority over existing treatments like Tamiflu and Xofluza in animal models of Influenza A/H3N2 lethal lung infection. NV-387 is also active against coronaviruses, RSV, and other viruses that use heparan sulfate features to infect human cells. The company emphasizes that NV-387’s unique mechanism makes it difficult for viruses to develop resistance, addressing a major limitation of current antiviral therapies. These findings highlight NV-387’s potential as a future dominant player in the treatment of acute and severe acute respiratory infections. The timeline for the presentation of these results has not been specified.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NanoViricides Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1126644) on January 13, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>NanoViricides Reports NV-387 Outperforms Tamiflu and Xofluza Against H3N2 in Animal Studies</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNanoViricides Reports NV-387 Outperforms Tamiflu and Xofluza Against H3N2 in Animal Studies\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2026-01-13 21:31</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      NanoViricides Reports NV-387 Outperforms Tamiflu and Xofluza Against H3N2 in Animal Studies\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/NNVC\">NanoViricides Inc.</a> has announced promising research results for its broad-spectrum antiviral drug candidate, NV-387. The company reports that NV-387 has demonstrated substantial superiority over existing treatments like Tamiflu and Xofluza in animal models of Influenza A/H3N2 lethal lung infection. NV-387 is also active against coronaviruses, RSV, and other viruses that use heparan sulfate features to infect human cells. The company emphasizes that NV-387’s unique mechanism makes it difficult for viruses to develop resistance, addressing a major limitation of current antiviral therapies. These findings highlight NV-387’s potential as a future dominant player in the treatment of acute and severe acute respiratory infections. The timeline for the presentation of these results has not been specified.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NanoViricides Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1126644) on January 13, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4568","symbol_name":"美國抗疫概念","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nNDL1bCYq6:1","article_id":"2603568254","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2603568254","pubTimestamp":1768311066,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"NanoViricides Inc. has announced promising research results for its broad-spectrum antiviral drug candidate, NV-387. The company reports that NV-387 has demonstrated substantial superiority over existing treatments like Tamiflu and Xofluza in animal models of Influenza A/H3N2 lethal lung infection. NV-387 is also active against coronaviruses, RSV, and other viruses that use heparan sulfate features to infect human cells. The company emphasizes that NV-387’s unique mechanism makes it difficult for viruses to develop resistance, addressing a major limitation of current antiviral therapies. These findings highlight NV-387’s potential as a future dominant player in the treatment of acute and severe acute respiratory infections. The timeline for the presentation of these results has not been specified.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated conte","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4568":"美国抗疫概念","NNVC":"NanoViricides Inc.","BK4139":"生物科技"},"translate_title":"NanoViricides报告NV-387在动物研究中对抗H3N2的表现优于达菲和Xofluza","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NNVC":0.9},"content_text":"NanoViricides Reports NV-387 Outperforms Tamiflu and Xofluza Against H3N2 in Animal Studies\n    \n\nNanoViricides Inc. has announced promising research results for its broad-spectrum antiviral drug candidate, NV-387. The company reports that NV-387 has demonstrated substantial superiority over existing treatments like Tamiflu and Xofluza in animal models of Influenza A/H3N2 lethal lung infection. NV-387 is also active against coronaviruses, RSV, and other viruses that use heparan sulfate features to infect human cells. The company emphasizes that NV-387’s unique mechanism makes it difficult for viruses to develop resistance, addressing a major limitation of current antiviral therapies. These findings highlight NV-387’s potential as a future dominant player in the treatment of acute and severe acute respiratory infections. The timeline for the presentation of these results has not been specified.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NanoViricides Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1126644) on January 13, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}